AI-Powered Therapeutic Selection and Orthotopic Efficacy Validation in Preclinical GBM Models
Learn about a personalized, AI-based approach to predict and test the efficacy of combination therapies in GBM. This longitudinal study features a unique pair of PDX models originating from the same patient: one from a surgical resection at initial GBM diagnosis, and another from subsequent recurrence—providing a unique opportunity to study disease progression, resistance, and novel treatment strategies.
Preclinical GBM Research in the Age of FDA Modernization and Predictive Artificial Intelligence
Explore an AI-supported platform built to advance GBM drug development. By integrating genomic profiling, phenotypic characterization, and clinical alignment, we help identify truly human-relevant models that maximize translational impact. Learn how to design orthotopic intracranial studies that align with modern FDA guidance under the Modernization Act while optimizing animal use through strategic experimental design. Discover how cutting-edge AI and machine learning tools can revolutionize model selection, sharpen therapeutic strategies, and accelerate biomarker-driven development—bridging the gap between preclinical research and clinical success.
Explore Certis’ GBM Resource Hub
BBB White Paper
Beyond the Barrier: Precision Preclinical Strategies for Targeting Glioblastoma
Real-Tme Visualization of Therapeutic Efficacy in GBM Cells
IncuCyte® Live-Cell Imaging reveals the differential response of glioblastoma model CRT00744 over 6 days: untreated cells show continued proliferation, while temozolomide-treated cells undergo growth arrest and apoptosis. Red fluorescence marks apoptotic cells, demonstrating the temporal dynamics of standard-of-care therapeutic response in real time.
“The team at Certis hits the mark in all respects: excellent scientific execution, great communication, and a rare degree of flexibility. When I need to outsource preclinical studies, Certis will be my first choice every time.”
- Rick Russell, CEO, Tract Bio
Why Choose Certis Oncology?
Robust and meaningful GBM drug development requires preclinical data that is predictive, reproducible, and translationally relevant. With deep experience developing orthotopic models and conducting intracranial studies, Certis is a trusted partner for accelerating biomarker discovery, de-risking development, and generating clear and compelling evidence of drug efficacy.
Deep Orthotopic Engraftment & Imaging Expertise
Specialized surgical teams deliver reproducible orthotopic GBM models that mirror human disease biology
Industry’s Most Extensive GBM PDX Collection
51 low-passage, highly characterized GBM models—including 21 pretreated specimens with 16 resistant to SoC
Predictive AI/ML & Data Analytics
Advanced AI/ML models and rigorous biostatistics transform complex data into therapeutic predictions and actionable Go/No-Go recommendations
PhD-Level Scientific Partnership
Expert collaboration and customized platforms deliver robust translational data for clear therapeutic answers.
Access Our 2026 GBM Summit Data
Download the Poster & Scientific Presentation
CLIA-Certified AAALAC Accredited OLAW Accredited
Your Translational Partner
Certis Oncology Solutions Certis Oncology delivers PhD-led, AI-powered preclinical oncology research that integrates predictive computational modeling, patient-derived tumor models, advanced imaging, and rigorous pharmacological characterization. With deep experience developing orthotopic models and conducting intracranial studies, we help GBM therapeutics developers accelerate biomarker discovery, de-risk development, and secure clear and compelling evidence of drug efficacy. Established in 2016, Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in Sorrento Valley, the heart of San Diego’s life sciences industry.
